Literature DB >> 18612439

Statins improve human coronary atherosclerotic plaque morphology.

Stephanie D Reilly1, Silvio H Litovsky, Michael P Steinkampf, James B Caulfield.   

Abstract

Statin treatment markedly reduces the incidence of acute coronary events in patients with coronary atherosclerosis. Although imaging studies have indirectly shown the beneficial effects of statins on plaque morphology, there has to our knowledge been no reported histologic comparison of the morphology of coronary plaque in statin-treated versus untreated patients who had substantial coronary artery atherosclerosis. We retrospectively studied arterial sections from the native hearts of patients who had experienced end-stage ischemic heart disease and subsequent cardiac transplantation. Of 44 qualified patients, 33 study patients had received pre-transplantation statin therapy, and 11 control patients had not. Pathologic examination of each explanted heart confirmed coronary artery disease and previous myocardial infarction in all patients. Diabetes mellitus was more prevalent in the study group. The groups were similar in levels of total and low-density lipoprotein cholesterol, and in the available number of arterial cross-sections per patient. All patients had plaques. High-grade lesions were found in 66.3% of cross-sections in the control group, and in 34.6% in the study group (P=0.011). Conversely, the degree of inflammation was markedly lower in the study group: low-grade fibrous plaques occurred in 45.7% of cross-sections in the study group, versus 11.3% in the control group (P=0.006). The study group had significantly fewer high-grade plaques and more fibrous plaques than did the control group at the time of transplantation. Our findings show that statin therapy substantially enhances plaque stabilization. We further suggest that reduction of plaque inflammation is an important aspect of this stabilization.

Entities:  

Keywords:  Antilipemic agents/therapeutic use; arteriosclerosis/drug therapy; coronary artery disease/classification/complications/drug therapy/pathology/prevention & control; coronary vessels/pathology; hydroxymethylglutaryl-CoA reductase inhibitors/therapeutic use; hyperlipidemias/blood/complications/drug therapy; immunohistochemistry; inflammation/drug therapy/physiopathology; macrophages/drug effects/pathology; muscle, smooth, vascular/drug effects/pathology; vascular patency/drug effects

Mesh:

Substances:

Year:  2008        PMID: 18612439      PMCID: PMC2435445     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  42 in total

Review 1.  Cholesterol lowering and coronary artery disease: mechanisms of risk reduction.

Authors:  R A Archbold; A D Timmis
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 2.  Vulnerable atherosclerotic plaque: a multifocal disease.

Authors:  Ward Casscells; Morteza Naghavi; James T Willerson
Journal:  Circulation       Date:  2003-04-29       Impact factor: 29.690

Review 3.  Importance of endothelial function in mediating the benefits of lipid-lowering therapy.

Authors:  B G Brown; X Q Zhao
Journal:  Am J Cardiol       Date:  1998-11-26       Impact factor: 2.778

Review 4.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

5.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.

Authors:  U Laufs; V La Fata; J Plutzky; J K Liao
Journal:  Circulation       Date:  1998-03-31       Impact factor: 29.690

6.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

7.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.

Authors:  G O'Driscoll; D Green; R R Taylor
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

8.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

9.  HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages.

Authors:  S Bellosta; D Via; M Canavesi; P Pfister; R Fumagalli; R Paoletti; F Bernini
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-11       Impact factor: 8.311

10.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins.

Authors:  M Essig; G Nguyen; D Prié; B Escoubet; J D Sraer; G Friedlander
Journal:  Circ Res       Date:  1998-10-05       Impact factor: 17.367

View more
  3 in total

1.  Carotid inflammation is unaltered by exercise in hypercholesterolemic Swine.

Authors:  Isabelle Masseau; Michael J Davis; Douglas K Bowles
Journal:  Med Sci Sports Exerc       Date:  2012-12       Impact factor: 5.411

2.  Effect of atorvastatin therapy on borderline vulnerable lesions in patients with acute coronary syndrome.

Authors:  Dan-Qing Yu; Shu-Guang Lin; Ji-Yan Chen; Ling Xue; Guang Li; Hao-Jian Dong; Ying-Ling Zhou
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

3.  Association between Obesity and Carotid Intima-Media Thickness in Korean Office Workers: The Mediating Effect of Physical Activity.

Authors:  Youngyun Jin; Donghyun Kim; Jinkyung Cho; Inhwan Lee; Kyuhwan Choi; Hyunsik Kang
Journal:  Biomed Res Int       Date:  2018-08-01       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.